In August 2025, Bayer announced a study of researchers will check the medical history and current medications of the participants. They will also perform a complete health check-up of all the ...

The AstraZeneca share price has been treading water for the past few years, but first-half results add strength to rising forecasts. The post Can this latest news kickstart AstraZeneca’s share price ...

Topline data were announced from a phase 3 trial that evaluated baxdrostat in patients with uncontrolled or treatment resistant hypertension.

Positive high-level results from the BaxHTN phase III trial showed baxdrostat at two doses (2mg and 1mg) demonstrated a statistically significant and clinically meaningful reduction in mean seated ...

"AstraZeneca’s Phase III trial of baxdrostat shows mean SBP reduction" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

AstraZeneca (AZ) has shared positive results from a late-stage study of its investigational oral aldosterone synthase inhibitor baxdrostat in patients with uncontrolled or treatment resistant ...

AstraZeneca’s Phase III BaxHTN trial shows that baxdrostat significantly lowers systolic blood pressure in resistant hypertension, meeting all key endpoints. With a projected US$5 billion peak in ...

Baxdrostat, a drug belonging to a new class of aldosterone synthase inhibitors, led to an average fall in blood pressure of 25 mmHg in clinical trials. This is two to three times the reduction ...

Astra said its experimental drug Baxdrostat reduced the blood pressure of patients who have a treatment-resistant form of hypertension.

Baxdrostat is described as a selective aldosterone synthase inhibitor, currently under investigation as a monotherapy for hypertension and primary aldosteronism, and in combination with dapagliflozin ...